普洛药业: 关于下属公司股权转让的公告

Transaction Overview - The company is optimizing its asset structure through a transaction where its wholly-owned subsidiary, Zhejiang Puluo Debang Pharmaceutical Co., Ltd., transfers 100% equity and a debt of 6.9 million yuan in Sichuan Xinquan Dong Health Technology Co., Ltd. to Sichuan Jingxin Electric Co., Ltd. [1] - The transfer price is based on the net asset value of 26.4683 million yuan as of June 30, 2024, assessed by Shanghai Shenwei Asset Appraisal Co., Ltd. [1] Transaction Details - The transaction does not require approval from the board of directors or shareholders and does not constitute a related party transaction or a major asset restructuring as per relevant regulations [2] - The buyer, Sichuan Jingxin Electric Co., Ltd., has total assets of 42.9828 million yuan and net assets of 9.5720 million yuan for the year 2024 [2] Target Company Information - The target company, Sichuan Xinquan Dong Health Technology Co., Ltd., has total assets of 5.6510 million yuan and a net asset deficit of 1.2635 million yuan for the year 2024 [3] - The target company reported no operating income for the first two months of 2025 and a net loss of 19.40 million yuan [3] Agreement Highlights - The transfer includes 100% equity and a debt of 6.9 million yuan [4] - The total transfer price for the equity is set at 30.18 million yuan, with a total of 35.08 million yuan to be deposited in a fund supervision account [4] Purpose and Impact of the Transaction - The transaction aims to further optimize the company's asset structure and aligns with its development strategy [5] - Post-transaction, the target company will no longer be included in the company's consolidated financial statements, and it is expected to increase the company's profit by approximately 27.60 million yuan for the year 2025 [5]